drugset
Drugs / ToleroMune HDM
last change May 2014 re-read 3 minutes ago

ToleroMune HDM

also known as TM-HDM · ToleroMune House Dust Mite

Vaccine

Developed for
allergic rhinitis · allergic disease
Investigated by
Adiga Life Sciences, Inc. · Circassia Limited · Cetero Research, San Antonio

Trials 3

today NCT01949441 · Ph 2 NCT01447784 · Ph 2 NCT01008332 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01949441 Sep 2013 → May 2014 allergic rhinitis Circassia Limited Completed No outcome recorded
Phase 2 NCT01447784 Sep 2011 → May 2013 allergic rhinitis Circassia Limited Completed No outcome recorded
Phase 2 NCT01008332 Nov 2009 → Aug 2010 allergic disease Circassia Limited Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Toleromune HDM “Biological: Toleromune HDM” NCT01008332 ↗
3

NCT01008332 ↗

NCT01949441 ↗

NCT01447784 ↗
Known as TM-HDM “ToleroMune House Dust Mite (TM-HDM), a combination of seven Synthetic Peptide Immuno-Regulatory Epitopes” NCT01949441 ↗
Known as ToleroMune House Dust Mite “ToleroMune House Dust Mite (TM-HDM), a combination of seven Synthetic Peptide Immuno-Regulatory Epitopes” NCT01949441 ↗
Modality Vaccine “ToleroMune HDM is a novel, synthetic, allergen-derived peptide desensitising vaccine” NCT01008332 ↗
Route Other “Intradermal injection 1 x 11 administrations 4 weeks apart” NCT01447784 ↗